Key cohort fully enrolled in EV-103 pembrolizumab/enfortumab vedotin bladder cancer trial

“If results of this study are compelling, we may have the opportunity to submit them to the FDA as part of an application for accelerated approval,” said Roger Dansey, MD.

Read the full article here

Related Articles